Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureChristoph Röllig
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Ziftomenib with venetoclax and azacitidine for relapsed/refractory NPM1-mutated acute myeloid leukemia
10.1182/blood.2026034043 · 2026
The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis
10.1016/j.cell.2005.09.025 · 2005
Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia
10.1158/2159-8290.cd-16-0237 · 2016
Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1
10.1038/s41375-022-01707-w · 2022
Ziftomenib in relapsed or refractory NPM1-mutated AML
10.1200/jco-25-01694 · 2025
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
10.1182/bloodadvances.2020003734 · 2021
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
10.1182/bloodadvances.2022008316 · 2023
A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents
10.1038/s41375-024-02501-6 · 2025
NPM1 and IDH1/2 mutations show limited prognostic impact in relapsed/refractory AML: evidence from the AVALON cohort
10.1002/hon.70169 · 2026
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial
10.1016/s1470-2045(24)00386-3 · 2024
No additional external references are available.